Advanced Search
Volume 39 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Abstract
References
Liu Haiyun, Cui Weihong, Xu Yingchun. Incidence and case survival status of cancer and influencing factors in Yantai, Shandong, 2012−2021[J]. Disease Surveillance, 2024, 39(10): 1328-1334. DOI: 10.3784/jbjc.202309180491
Citation: Liu Haiyun, Cui Weihong, Xu Yingchun. Incidence and case survival status of cancer and influencing factors in Yantai, Shandong, 2012−2021[J]. Disease Surveillance, 2024, 39(10): 1328-1334. DOI: 10.3784/jbjc.202309180491
shu

Incidence and case survival status of cancer and influencing factors in Yantai, Shandong, 2012−2021

  • 1.

    Medical Department, Shandong Junior College of Traditional Chinese Medicine, Yantai 264199, Shandong, China

  • 2.

    Gaoxin District Center for Disease Control and Prevention, Yantai 264000, Shandong, China

Funds: This study was supported by the fund for Shandong Medical and Health Science and Technology Development Plan Project (No. 202115011016)
More Information
  • Received Date: September 17, 2023
  • Available Online: July 14, 2024
  • Published Date: February 25, 2024
    Graphical Abstract
    • Abstract
  • Objectives 

    To understand the incidence trend, case survival status of cancer and influencing factors in Yantai of Shandong province, and provide data support for the prognosis evaluation and prevention of cancer.

    Methods 

    The follow-up and registration data of cancer cases collected from Yantai Cancer Registry from 2012 to 2021 were used to calculate the incidence rate and constituent. Annual percent of change (APC) was used to analyze the trend of incidence. The survival rate and median survival time were calculated by Kaplan-Meier method. Log-Rank test was used for comparison of survival rates between or among groups. Cox proportional hazards regression model was used for univariate and multivariate survival analysis.

    Results 

    A total of 233 097 cancer cases were reported in Yantai from 2012 to 2021, the crude incidence rate was 357.16/100 000, the age standardized mortality rates based on China population and world population were 224.63/100 000 and 222.23/100 000 respectively; which were all showed increasing trends year by year with APC=4.67%, APC=4.85% and APC=4.90% (all P<0.001); the incidence rate was higher in men than in women and in rural area than in urban area (χ2=4 022.551, χ2=330.024, all P<0.001), but the upward trend was greater in women (APC=5.66%, P<0.001)than in men (APC=3.95%, P<0.001)and in urban area (APC=6.69%, P<0.001)than in rural area (APC=3.28%, P=0.004). The incidence rate increased with age in the past decade (trend χ2=383 334.330, P<0.001), with the higher increase in age group 65-74 years (APC=7.30%, P<0.001) and <35 years (APC=6.71%, P=0.001). The incidence of epithelial malignancy was highest (204.27/100 000)and showed the largest upward trend (APC=9.850%, P<0.001). The median survival time in the cancer cases in Yantai was 2.05 years (95% confidence interval: 2.03−2.07)and the 5-year survival rate was 41.74% with the highest of breast cancer cases (81.12%)and the lowest of pancreatic cancer cases (11.01%). Cox regression analysis showed that the period of diagnosis, gender, area, age and pathological type were the influencing factors of the survival status of the cancer cases (all P<0.05).

    Conclusion 

    In the past decade, the incidence of cancer increased gradually in Yantai, especially in younger population, but the survival status was significantly improved. It is necessary to further strengthen the comprehensive prevention and control of priority cancer and in patients with poor survival.

    • FullText(HTML)
    • References (16)
  • [1]
    Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115−132. DOI: 10.3322/caac.21338.
    [2]
    Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783−791. DOI: 10.1097/CM9.0000000000001474.
    [3]
    Wei WQ, Zeng HM, Zheng RS, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020, 21(7): e342−349. DOI: 10.1016/S1470−2045(20)30073−5.
    [4]
    Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555−567. DOI: 10.1016/S2214−109X(18)30127−X.
    [5]
    王茂波, 刘海韵, 张红杰. 烟台市居民死因分析及疾病负担研究[M]. 北京: 中国轻工业出版社, 2022: 34−35.

    Wang MB, Liu HY, Zhang HJ. Burden of disease study among residents in Yantai[M]. Beijing: China Light Industry Press, 2022: 34−35.
    [6]
    Cao MM, Li H, Sun DQ, et al. Current cancer burden in China: epidemiology, etiology, and prevention[J]. Cancer Biol Med, 2022, 19(8): 1121−1138. DOI: 10.20892/j.issn.2095−3941.2022.0231.
    [7]
    Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity[J]. Lancet, 2014, 383(9916): 564−573. DOI: 10.1016/S0140−6736(13)62225−4.
    [8]
    Fritz A, Percy C, Jack A, 等. 国际疾病分类肿瘤学专辑[M]. 董景五, 译. 3版. 北京: 人民卫生出版社, 2003: 17-31.

    Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology[M]. Dong JW, trans. 3rd ed. Beijing: People’s Medical Publishing House, 2003: 17-31.
    [9]
    国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社, 2016: 59−75.

    National Cancer Center. Chinese guideline for cancer registration, 2016[M]. Beijing: People’s Medical Publishing House, 2016: 59−75.
    [10]
    马霞, 张军, 王旭峰, 等. 2020年山东省济南市居民恶性肿瘤流行情况及2016-2020年变化趋势分析[J]. 中国肿瘤,2022,31(2):98−104. DOI:10.11735/j.issn.1004−0242.2022.02.A003.

    Ma X, Zhang J, Wang XF, et al. Cancer incidence and mortality in Jinan city in 2020 and trend from 2016 to 2020[J]. China Caner, 2022, 31(2): 98−104. DOI: 10.11735/j.issn.1004−0242.2022.02.A003.
    [11]
    应莉娅, 朱洪挺, 胡浩, 等. 2013-2019年永康市恶性肿瘤发病趋势分析[J]. 预防医学,2023,35(11):970−974. DOI:10.19485/j.cnki.issn2096−5087.2023.11.012.

    Ying LY, Zhu HT, Hu H, et al. Trends in incidence of malignant tumors in Yongkang city from 2013 to 2019[J]. Prev Med, 2023, 35(11): 970−974. DOI: 10.19485/j.cnki.issn2096−5087.2023.11.012.
    [12]
    Huang JJ, Ngai CH, Deng YY, et al. Cancer incidence and mortality in Asian countries: a trend analysis[J]. Cancer Control, 2022, 29: 1−11. DOI: 10.1177/10732748221095955.
    [13]
    Xia CF, Dong XS, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584−590. DOI: 10.1097/CM9.0000000000002108.
    [14]
    Qiu HB, Cao SM, Xu RH. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10): 1037−1048. DOI: 10.1002/cac2.12197.
    [15]
    Sun DQ, Li H, Cao MM, et al. Cancer burden in China: trends, risk factors and prevention[J]. Cancer Biol Med, 2020, 17(4): 879−895. DOI: 10.20892/j.issn.2095−3941.2020.0387.
    [16]
    Zeng CJ, Wen WQ, Morgans AK, et al. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010[J]. JAMA Oncol, 2015, 1(1): 88−96. DOI: 10.1001/jamaoncol.2014.161.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (158) PDF downloads (24) Cited by()
    Related

    CopyRight © 2008 Disease Surveillance

    TEL: 010-58900732 Email: jbjc@icdc.cn  京ICP备11024750号    京公网安备 11011402013027号

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return